Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.
Although a bookwork in 2012 suggested a cancer numb could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now try to say they have been unable to duplicate those findings. The teams said their inquire into could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has pensive side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer poison with bare side effects," said study co-author Robert Vassar, a professor of apartment and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.

This study should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering gear of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to discuss refractory cutaneous T-cell lymphoma. Once approved, however, the pharmaceutical also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to like blazes reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the sign study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the advance of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the example research, admitted being skeptical about the initial findings.